

# Performance in Initiating Research (PIN);

## Studies given NHS Permission between 01/04/2015 – 01/04/2016 (Q4)

Local ID	Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:				
15-03-04	75195	12/LO/1322	99922	NHS Permission	Diabetes Prevention using SMS	19/05/2015	20/05/2015	Yes	14/07/2015	1	65	56	Yes																								
15-02-09	75196	13/EM/0251	13150	NHS Permission	Serelain when added to standard therapy in acute heart failure	27/04/2015	30/04/2015	No		3			No													Y									Patients failing to meet the inclusion criteria (as they must be recruited in a very strict time frame at presentation). Patients are being managed in community leading to reduced opportunity to screen.	Neither	
14-08-05	75197	13/LO/1096	89630	NHS Permission	MD-FRAX PROJECT	11/05/2015	11/05/2015	Yes	24/06/2015	0	44	44	Yes																								
15-04-04	75198	14/SC/1219	159391	NHS Permission	AIRWAYS-2	14/04/2015	18/05/2015	Yes	10/11/2015	34	176	210	No											Y							Y			Delay in first patients seen; Consent follows patient recruitment. Patient survival is only 20% and therefore likelihood of being able to identify an eligible patient is severely reduced. Benchmark not met. RA submitted as single SS. Sponsor failed to name local collaborator, ITU consultant, ED consultant, or ED research nurse.	Neither		
14-12-02	75199	13/EE/0038	111368	NHS Permission	HALT-IT	13/05/2015	10/06/2015	No		26			No												Y											New PI has recently been selected.	NHS Provider
13-04-13	75200	12/NM/0766	56508	NHS Permission	PREDNOS 2	18/08/2015	24/08/2015	Yes	25/08/2015	6	1	7	Yes																								
15-02-02	75201	14/SS/1096	164274	NHS Permission	RAPD DCTA	22/10/2015	28/10/2015	Yes	17/12/2015	4	52	56	Yes																								
15-05-10	75202	14/EM/1267	166568	NHS Permission	PARADIGM LC2696 in patients from Paradigm HF study	12/11/2015	12/11/2015	Yes	30/11/2015	0	18	18	Yes																								
15-05-04	75203	14/WA/1056	154468	NHS Permission	AML 19	03/12/2015	03/12/2015	No		0			No																		Y			Delays in uploading the local chemotherapy regime to the Chemocare Prescribing system by the Y&H C&BN	Neither		
15-10-02	75204	15/YH/0428	188418	NHS Permission	DUAL VII	18/12/2015	18/12/2015	No		0			No																						Recruitment is proving difficult as patients are not consenting to the trial while in care at the hospital. There is hope that the recruitment figure may increase with efforts in community care.	Neither	
15-04-12	75213	15/NM/0156	168118	NHS Permission	SENIOR (Assessing the Safety and Efficacy of HDE901U300 Versus Lantus in Older Patients with Type 2 Diabetes Inadequately Controlled on Antidiabetic Regimens Either including no insulin, or with Basal Insulin as Their Only Insulin)	13/06/2015	25/06/2015	Yes	06/10/2015	12	103	115	No																						Recruitment is proving difficult as patients are not consenting to the trial while in consultation at the hospital.	Neither	
15-05-09	75214	14/YH/0085	126738	NHS Permission	FLAIR (Front-line therapy in CLL: Assessment of Brintellix® (Vortioxetine) in CLL)	24/03/2016	24/03/2016	No		0			Within 70 Days													Y									Newly approved study. No patients have yet been seen that meet the inclusion criteria.	Neither	
15-06-04	75215	15/SC/0115	167894	NHS Permission	Hemorrhagic Outcomes (Study to determine the effect of sitagliptin when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus)	06/10/2015	08/10/2015	Yes	06/11/2015	2	29	31	Yes									Y															
15-10-04	75216	15/YH/0458	188061	NHS Permission	SMART COPD	21/03/2016	24/03/2016	No		3			Within 70 Days																							Newly approved study. No patients have yet been seen that meet the inclusion criteria.	Neither

## Performance in Delivering Research (PID);

### Commercial Studies closed to Recruitment between 01/04/2015 – 01/04/2016 (Q4)

Local ID	Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
14-01-10	2969	13/EE/0449	143616	REPLACE	Number Agreed	8	8	Date Agreed	15/05/2015	13	15/05/2015	Recruitment Finished	
09-11-05	2971	09/H0406/110	131150	PARADIGM	Number Agreed	6	6	Date Agreed	15/01/2016	6	15/01/2016	Recruitment Finished	